FDA OKs Sapien Valve As Pivotal Trial Control Prior To Marketing Approval

Edwards Lifesciences says FDA will support use of the firm's investigational Sapien transcatheter aortic heart valve as a control treatment in an upcoming trial of the firm’s next-generation Sapien XT.